Kura Oncology reported a transformative QQ4 2024 quarter driven by a first meaningful collaboration revenue stream from Kyowa Kirin, totaling $53.9 million, enabling the company to markedly reduce quarterly net loss to $19.2 million on a GAAP basis despite ongoing R&D and G&A investments. The quarter underscores the company’s shift from a predominantly R&D-stage funding model to near-term NDA readiness for ziftomenib and multi-program advancement across AML and solid tumor initiatives. Management highlighted alignment with FDA and EMA on accelerated approval pathways for frontline AML, the potential MRD-negative CR endpoints, and plans to submit the NDA for ziftomenib in Q2 2025. The balance sheet remains exceptionally strong, with $727.4 million in cash, cash equivalents and short-term investments as of 12/31/2024 (including a $330 million upfront Kyowa Kirin payment), supporting operations into 2027 and commercialization readiness in frontline AML under the Kyowa Kirin collaboration. Management also outlined a robust 2025 milestone slate, including KOMET-017 trials in frontline AML (intense and non-intensive), KOMET-015 in GIST, and continued development of the farnesyl transferase inhibitor (FTI) program KO-2806. While near-term revenue visibility is solid via collaboration, execution risk remains in obtaining regulatory approvals, clinical readouts, and scalable commercialization. Overall, the blend of sizable collaboration revenue, a debt-free balance sheet, and a clear regulatory path for ziftomenib positions KURA for meaningful upside, tempered by typical biotech execution risk and competitive dynamics in AML.